HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.

Abstract
Hepatocellular cancer (HCC) remains a significant therapeutic challenge due to its poorly understood molecular basis. In the current study, we investigated two independent cohorts of 249 and 194 HCC cases for any combinatorial molecular aberrations. Specifically we assessed for simultaneous HMET expression or hMet activation and catenin β1 gene (CTNNB1) mutations to address any concomitant Met and Wnt signaling. To investigate cooperation in tumorigenesis, we coexpressed hMet and β-catenin point mutants (S33Y or S45Y) in hepatocytes using sleeping beauty transposon/transposase and hydrodynamic tail vein injection and characterized tumors for growth, signaling, gene signatures, and similarity to human HCC. Missense mutations in exon 3 of CTNNB1 were identified in subsets of HCC patients. Irrespective of amino acid affected, all exon 3 mutations induced similar changes in gene expression. Concomitant HMET overexpression or hMet activation and CTNNB1 mutations were evident in 9%-12.5% of HCCs. Coexpression of hMet and mutant-β-catenin led to notable HCC in mice. Tumors showed active Wnt and hMet signaling with evidence of glutamine synthetase and cyclin D1 positivity and mitogen-activated protein kinase/extracellular signal-regulated kinase, AKT/Ras/mammalian target of rapamycin activation. Introduction of dominant-negative T-cell factor 4 prevented tumorigenesis. The gene expression of mouse tumors in hMet-mutant β-catenin showed high correlation, with subsets of human HCC displaying concomitant hMet activation signature and CTNNB1 mutations.
CONCLUSION:
We have identified cooperation of hMet and β-catenin activation in a subset of HCC patients and modeled this human disease in mice with a significant transcriptomic intersection; this model will provide novel insight into the biology of this tumor and allow us to evaluate novel therapies as a step toward precision medicine. (Hepatology 2016;64:1587-1605).
AuthorsJunyan Tao, Emily Xu, Yifei Zhao, Sucha Singh, Xiaolei Li, Gabrielle Couchy, Xin Chen, Jessica Zucman-Rossi, Maria Chikina, Satdarshan P S Monga
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 64 Issue 5 Pg. 1587-1605 (11 2016) ISSN: 1527-3350 [Electronic] United States
PMID27097116 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2016 by the American Association for the Study of Liver Diseases.
Chemical References
  • CTNNB1 protein, mouse
  • beta Catenin
  • MET protein, human
  • Proto-Oncogene Proteins c-met
Topics
  • Animals
  • Carcinoma, Hepatocellular (genetics)
  • Gene Expression Regulation, Neoplastic
  • Liver Neoplasms (genetics)
  • Male
  • Mice
  • Models, Biological
  • Point Mutation
  • Proto-Oncogene Proteins c-met (genetics)
  • beta Catenin (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: